Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.74 |
| ▸ | MMP8 | P22894 | 8/20 | 0.74 |
| ▸ | MMP9 | P14780 | 7/20 | 0.74 |
| ▸ | MMP13 | P45452 | 7/20 | 0.74 |
| ▸ | MMP1 | P03956 | 6/20 | 0.74 |
| ▸ | MMP3 | P08254 | 6/20 | 0.74 |
| ▸ | MMP7 | P09237 | 6/20 | 0.74 |
| ▸ | MMP14 | P50281 | 5/20 | 0.74 |
| ▸ | CA12 | O43570 | 4/20 | 0.73 |
| ▸ | CA2 | P00918 | 4/20 | 0.73 |
| ▸ | CA9 | Q16790 | 4/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.73 |
| ▸ | CA1 | P00915 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7409476 | 1.00 | MMP2 (0.74) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL7648565 | 0.85 | MMP2 (1.00) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL7648573 | 0.85 | MMP2 (1.00) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL7651281 | 0.82 | MMP2 (0.66) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL7375064 | 0.82 | MMP2 (0.66) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL9435889 | 0.79 | MMP2 (1.00) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL7413590 | 0.77 | MMP2 (0.66) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL7413588 | 0.77 | MMP2 (0.66) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL11767663 | 0.76 | MMP2 (0.65) | MMP2MMP8MMP9MMP13MMP1 | |
| SCHEMBL7408889 | 0.75 | MMP2 (1.00) | MMP2MMP8MMP9MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6500811-B2 | PROPHYLAXIS AND THERAPY OF DISORDERS IN THE COURSE OF WHICH AN INCREASED ACTIVITY OF MATRIX-DEGRADING ENZYMES IS INVOLVED; THESE INCLUDE DEGENERATIVE JOINT DISORDERS SUCH AS OSTEOARTHROSES AND DISORDERS OF CONNECTIVE TISSUE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-31 | — | — | US | disclosed |
| EP-1097159-B1 | PHOSPHINOUS AND PHOSPHONIC ACID DERIVATIVES USED AS MEDICAMENTS | AVENTIS PHARMA GMBH (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-20020082246-A1 | Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2002-06-27 | — | — | US | disclosed |
| US-6235727-B1 | ENZYME INHIBITORS; MUSCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-22 | — | — | US | disclosed |
| EP-1097159-A1 | PHOSPHINOUS AND PHOSPHONIC ACID DERIVATIVES USED AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000004030-A1 | PHOSPHINOUS AND PHOSPHONIC ACID DERIVATIVES USED AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082246-A1 | Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use | ARSA, STS, PNPO | MMP2 24/4885MMP8 205/4885MMP9 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.